Eris Lifesciences (NSE:ERIS) ROCE %: 15.51% (As of Mar. 2026)


NSE:ERIS Eris Lifesciences Ltd NSE:ERIS
91 GF Score
Price ₹1,459.00
GF Value ₹1,642.12
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eris Lifesciences ROCE %?

Eris Lifesciences NSE:ERIS -0.50% 91 ROCE % is 15.51% as of Mar. 2026. GuruFocus rates NSE:ERIS with a GF Score™ of 91/100 and a GF Value™ of ₹1,642.12 (Modestly Undervalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Eris Lifesciences's annualized ROCE % for the quarter that ended in Mar. 2026 was 15.51%.

Eris Lifesciences  (NSE:ERIS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Eris Lifesciences ROCE % Related Terms

Eris Lifesciences ROCE % Historical Data

* Premium members only.

The historical data trend for Eris Lifesciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eris Lifesciences ROCE % Chart

Eris Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.87 16.27 13.35 14.18 15.20

Eris Lifesciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.96 14.85 15.77 13.78 15.51
NSE:ERIS
91GF Score
Eris Lifesciences Ltd NSE:ERIS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eris Lifesciences ROCE % Calculation

Eris Lifesciences's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=8312.1/( ( (70331.7 - 13813.9) + (73655.1 - 20771) )/ 2 )
=8312.1/( (56517.8+52884.1)/ 2 )
=8312.1/54700.95
=15.20 %

Eris Lifesciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=8201.2/( ( (0 - 0) + (73655.1 - 20771) )/ 1 )
=8201.2/( ( 0 + 52884.1 )/ 1 )
=8201.2/52884.1
=15.51 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 15.51% mean?
Eris Lifesciences (NSE:ERIS) has a ROCE % of 15.51% as of Mar. 2026.
Is Eris Lifesciences' ROCE % too high?
Eris Lifesciences' current ROCE % is 15.51%. The Drug Manufacturers industry median ROCE % is 7.01. Eris Lifesciences' value of 15.51% is 121.3% above this industry median. Overall, Eris Lifesciences has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' ROCE % compare to ZTS and UTHR?
Eris Lifesciences' ROCE % of 15.51% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. Eris Lifesciences' value of 15.51% is 121.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eris Lifesciences's current ROCE % of 15.51% is 121.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eris Lifesciences's current ROCE % is 15.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (NSE:ERIS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,642.12, compared to a current price of ₹1,459.00 — trading 11.2% below its estimated fair value. The current ROCE % is 15.51% and 121.3% above the Drug Manufacturers industry median of 7.01. Eris Lifesciences' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Eris Lifesciences (NSE:ERIS), the current ROCE % is 15.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eris Lifesciences (NSE:ERIS) Overvalued in 2026?

Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued. The current stock price of ₹1,459.00 is trading 11.2% below its estimated GF Value™ of ₹1,642.12. GuruFocus considers Eris Lifesciences to be Modestly Undervalued.

Key valuation signals for NSE:ERIS:

  • ROCE %: 15.51%
  • GF Value™: ₹1,642.12 vs. price of ₹1,459.00 (11.2% below fair value)
  • GF Score™: 91/100 with 6 warning signs
  • Industry Position: 121.3% above the Drug Manufacturers median

No single metric tells the full story. See the NSE:ERIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eris Lifesciences Business Description

Other Exchanges 540596:India
Address Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
91GF Score

Get the complete analysis for NSE:ERIS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,459.00
Price
₹1,642.12
GF Value